NCT06984146RecruitingPhase 2
Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
Flat-dose Nivolumab (40 mg) in Combination With Doxorubicin, Vinblastine, and Dacarbazine (AVD) for Newly Diagnosed Advanced Classic Hodgkin Lymphoma
Source: ClinicalTrials.gov · Last updated 26 Nov 2025
Brief summary (registry, in English)
The aim of the current trial is to evaluate the efficacy and safety of flat-dose nivolumab (40 mg) in combination with AVD in the management of patients with newly diagnosed advanced classic Hodgkin Lymphoma
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 54 (estimated)
- First submitted
- 2 May 2025
- Start date
- 15 Apr 2025
- Primary completion date
- Jan 2028
- Lead sponsor
- National Medical Research Radiological Centre of the Ministry of Health of Russia
- Diseases
- Hodgkin lymphoma
- NCT number
- NCT06984146
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 54
- From 15 Apr 2025 to the primary completion date, Jan 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Uncontrolled infection
Lab values
- Organ failure (e.g. creatinine \> 2x ULN; ALT or AST \> 5x ULN; bilirubin \> 2x ULN; hemodynamic instability; respiratory failure \> Grade 1)
Other
- Pregnancy
- Inability to sign informed consent
Who the study is looking for
- Newly-diagnosed histologically verified advanced stage (IIB-IV as per GHSG) classic Hodgkin lymphoma
- No past history of autoimmune disease
- Age \> 18 years
- Ejection fraction \> 50%
- ECOG 0-4
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| P. Hertsen Moscow Oncology Research Institute (MORI) for administrative and economic work - the branch of the FSBI "National Medical Research Radiological Centre" (NMRRC) of the Ministry of Health of the Russian Federation Coordinator of this site? Confirm its status | Moscow | Russia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.